Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

61. Contribution of oxytocin receptor polymorphisms to amygdala activation in schizophrenia spectrum disorders

Contribution of oxytocin receptor polymorphisms to amygdala activation in schizophrenia spectrum disorders 27847593 2018 11 13 2056-4724 2 6 2016 Nov BJPsych open BJPsych Open Contribution of oxytocin receptor polymorphisms to amygdala activation in schizophrenia spectrum disorders. 353-358 Oxytocin has been proposed to mediate amygdala dysfunction associated with altered emotion processing in schizophrenia, but the contribution of oxytocin pathway genes is yet to be investigated. To identify (...) potential different contributions of three oxytocin receptor polymorphisms (rs53576, rs237902 and rs2254298) between patients with schizophrenia spectrum disorders (SCZ), affective spectrum disorders (AD) and healthy controls (HC). In a total of 346 participants (104 with SCZ, 100 with AD, and 142 HC) underwent genotyping and functional magnetic resonance imaging (fMRI) during an emotional faces matching paradigm. Genetic association analyses were performed to test the possible effects on task-induced

BJPsych open2016 Full Text: Link to full Text with Trip Pro

62. Effect of transcranial direct current stimulation (tDCS) over the prefrontal cortex combined with cognitive training for treating schizophrenia: a sham-controlled randomized clinical trial.

Effect of transcranial direct current stimulation (tDCS) over the prefrontal cortex combined with cognitive training for treating schizophrenia: a sham-controlled randomized clinical trial. 27737311 2016 10 13 2017 03 17 2017 03 17 2238-0019 38 3 2016 Jul-Sep Trends in psychiatry and psychotherapy Trends Psychiatry Psychother Effect of transcranial direct current stimulation (tDCS) over the prefrontal cortex combined with cognitive training for treating schizophrenia: a sham-controlled (...) randomized clinical trial. 175-177 S2237-60892016000300175 10.1590/2237-6089-2015-0043 We report a transcranial direct current stimulation (tDCS) protocol over the dorsolateral prefrontal cortex (DLPFC) combined with cognitive training in schizophrenia. We assessed psychotic symptoms in nine patients using the Positive and Negative Syndrome Scale (PANSS). All evaluations were scored at baseline, at the end of the intervention protocol, and during a 4-week follow-up. The tDCS protocol consisted of 10 consecutive

Trends in psychiatry and psychotherapy2016

63. Loss of relational continuity of care in schizophrenia: associations with patient satisfaction and quality of care

Loss of relational continuity of care in schizophrenia: associations with patient satisfaction and quality of care 27713834 2018 11 13 2056-4724 2 5 2016 Sep BJPsych open BJPsych Open Loss of relational continuity of care in schizophrenia: associations with patient satisfaction and quality of care. 318-322 Users of mental health service are concerned about changes in clinicians providing their care, but little is known about their impact. To examine associations between changes in staff (...) , and patient satisfaction and quality of care. A national cross-sectional survey of 3379 people aged 18 or over treated in secondary care for schizophrenia or schizoaffective disorder. Nearly 41.9% reported at least one change in their key worker during the previous 12 months and 10.5% reported multiple changes. Those reporting multiple changes were less satisfied with their treatment and less likely to report having a care plan, knowing how to obtain help when in a crisis or to have had recommended

BJPsych open2016 Full Text: Link to full Text with Trip Pro

64. Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial.

Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial. 27703725 2016 10 05 2017 02 20 1 1 2015 Jun BJPsych open BJPsych Open Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial. 67-73 Clozapine causes significant metabolic disturbances including obesity and type 2 diabetes (...) . Recent evidence that reduced glucagon-like-peptide-1 (GLP-1) may contribute to aetiology of clozapine-associated metabolic dysregulation suggests a potential therapeutic role for GLP-1 agonists. This open-label, pilot randomised controlled trial evaluates the effect of exenatide in clozapine-treated obese adults who have schizophrenia, with or without poorly controlled diabetes. Sixty out-patients will be randomised to once weekly extended release exenatide or treatment as usual for 24 weeks

BJPsych open2016 Full Text: Link to full Text with Trip Pro

65. Psychiatric symptoms in individuals who use ketamine versus methamphetamine-implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study.

Psychiatric symptoms in individuals who use ketamine versus methamphetamine-implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study. DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Lancet2016

67. WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia.

WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. BACKGROUND: Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics. The efficacy of risperidone has already been compared to conventional drugs, but it remains unclear how risperidone compares (...) with other atypical antipsychotic drugs such as clozapine. OBJECTIVES: To determine the effects of risperidone compared with other atypical antipsychotic drugs for schizophrenia. SEARCH METHODS: Electronic searches of Biological Abstracts (1980-1999), The Cochrane Library (Issue 1, 2000), The Cochrane Schizophrenia Group's Register (January 1999), EMBASE (1980-1999), MEDLINE (1966-1999), LILACS (1982-1999), PSYNDEX (1977-1999) and PsycLIT (1974-1999) were undertaken. In addition, pharmaceutical databases

Cochrane2016

68. Paliperidone (palmitate 3-monthly) (Trevicta) - maintenance treatment of schizophrenia

Paliperidone (palmitate 3-monthly) (Trevicta) - maintenance treatment of schizophrenia Published 12 September 2016 Product Update: paliperidone palmitate 175mg, 263mg, 350mg, 525mg prolonged release suspension for injection (Trevicta ® ) SMC No. (1181/16) Janssen-Cilag Ltd 05 August 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission paliperidone palmitate (Trevicta ® ) is accepted for use within NHS Scotland. Indication under review: paliperidone palmitate (Trevicta ® ), a three-monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on one-monthly paliperidone palmitate injectable product. This new formulation of paliperidone palmitate is administered every three months and is available at pro-rata

Scottish Medicines Consortium2016

69. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial

Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial 27438995 2016 09 08 2017 05 08 2017 05 08 2168-6238 73 9 2016 Sep 01 JAMA psychiatry JAMA Psychiatry Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial. 947-54 10.1001/jamapsychiatry.2016.1383 A substantial proportion of women with schizophrenia experience debilitating treatment-refractory symptoms. The efficacy (...) of estrogen in modulating brain function in schizophrenia has to be balanced against excess exposure of peripheral tissue. Raloxifene hydrochloride is a selective estrogen receptor modulator (mixed estrogen agonist/antagonist) with potential psychoprotective effects and fewer estrogenic adverse effects. To determine whether adjunctive raloxifene therapy reduces illness severity in women with refractory schizophrenia. This 12-week, double-blind, placebo-controlled, randomized clinical trial

EvidenceUpdates2016

70. Olanzapine (ZypAdhera) - maintenance treatment of adult patients with schizophrenia

Olanzapine (ZypAdhera) - maintenance treatment of adult patients with schizophrenia %PDF-1.5 %���� 47 0 obj > endobj 62 0 obj >/Filter/FlateDecode/ID[ ]/Index[47 28]/Info 46 0 R/Length 79/Prev 195937/Root 48 0 R/Size 75/Type/XRef/W[1 2 1]>>stream h�bbd``b`j�S@D�`M� @���� "�A�;�pIh��M�Pܑ@�P/#�> ����4�?��o�� endstream endobj startxref 0 %%EOF 74 0 obj >stream h�b``�e``*g�8P#�0p4 ��B1��� �K{�C�� S����>00p��kh�����bs��?.QFY��o D endstream endobj 48 0 obj >/Metadata 2 0 R/PageLayout/OneColumn/Pages

All Wales Medicines Strategy Group2016

71. Bulking up the hippocampus in schizophrenia: a role for 5-HT1A agonists?

Bulking up the hippocampus in schizophrenia: a role for 5-HT1A agonists? 27703789 2018 11 13 2056-4724 2 4 2016 Jul BJPsych open BJPsych Open Bulking up the hippocampus in schizophrenia: a role for 5-HT 1A agonists? e10-e11 The volume of the hippocampus is reduced in patients with schizophrenia, and this deficit tends to become more pronounced with chronicity. Newer antipsychotics may protect against the progressive reductions in hippocampal volume while preliminary data offer hope

BJPsych open2016 Full Text: Link to full Text with Trip Pro

72. Cariprazine (Vraylar) for schizophrenia and acute manic or mixed episodes in bipolar I disorder

Cariprazine (Vraylar) for schizophrenia and acute manic or mixed episodes in bipolar I disorder Cariprazine (Vraylar) for schizophrenia and acute manic or mixed episodes in bipolar I disorder Cariprazine (Vraylar) for schizophrenia and acute manic or mixed episodes in bipolar I disorder HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc (...) .. Cariprazine (Vraylar) for schizophrenia and acute manic or mixed episodes in bipolar I disorder. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' conclusions Description of Technology: Cariprazine (Vraylar) is an orally administered atypical antipsychotic agent used to treat patients with acute exacerbation of schizophrenia or acute manic or mixed episodes associated with bipolar I disorder. Among antipsychotic drugs, the binding affinity profile of cariprazine is most similar

Health Technology Assessment (HTA) Database.2016

73. Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial

Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found

NIHR HTA programme2016

74. Dietary advice for people with schizophrenia.

Dietary advice for people with schizophrenia. BACKGROUND: People with serious mental illness have consistently higher levels of mortality and morbidity than the general population. They have greater levels of cardiovascular disease, metabolic disease, diabetes, and respiratory illness. Although genetics may have a role in the physical health problems of these people, lifestyle and environmental factors such as smoking, obesity, poor diet, and low levels of physical activity play a prominent (...) part. OBJECTIVES: To review the effects of dietary advice for schizophrenia and schizophrenia-like psychosis. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Trials Register (September 09, 2013 and February 24, 2016). SELECTION CRITERIA: We planned to include all randomised clinical trials focusing on dietary advice versus standard care. DATA COLLECTION AND ANALYSIS: The review authors (RP, KTP) independently screened search results but did not identify any studies that fulfilled

Cochrane2016

75. Refugee migration and risk of schizophrenia and other non-affective psychoses: cohort study of 1.3 million people in Sweden.

Refugee migration and risk of schizophrenia and other non-affective psychoses: cohort study of 1.3 million people in Sweden. OBJECTIVE: To determine whether refugees are at elevated risk of schizophrenia and other non-affective psychotic disorders, relative to non-refugee migrants from similar regions of origin and the Swedish-born population. DESIGN: Cohort study of people living in Sweden, born after 1 January 1984 and followed from their 14th birthday or arrival in Sweden, if later, until (...) except sub-Saharan Africa. Both refugees and non-refugee migrants from sub-Saharan Africa had similarly high rates relative to the Swedish-born population. CONCLUSIONS: Refugees face an increased risk of schizophrenia and other non-affective psychotic disorders compared with non-refugee migrants from similar regions of origin and the native-born Swedish population. Clinicians and health service planners in refugee receiving countries should be aware of a raised risk of psychosis in addition to other

BMJ2016

76. Understanding causes of and developing effective interventions for schizophrenia and other psychoses

Understanding causes of and developing effective interventions for schizophrenia and other psychoses Understanding causes of and developing effective interventions for schizophrenia and other psychoses Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need

NIHR HTA programme2016

77. Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study

Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study 26651392 2016 06 01 2017 05 01 2017 05 01 1535-7228 173 6 2016 Jun 01 The American journal of psychiatry Am J Psychiatry Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study. 600-6 10.1176/appi.ajp.2015.15050618 Although mortality related (...) to psychotropic medications has received much attention in recent years, little is known about the relationship between risk of death and cumulative antipsychotic load, and even less about the relationship between mortality and cumulative exposure to antidepressants or benzodiazepines. The authors examined these relationships using nationwide databases. The authors used prospectively collected nationwide databases to identify all individuals 16-65 years of age with a schizophrenia diagnosis (N=21,492

EvidenceUpdates2016

78. Schizophrenia.

Schizophrenia. Schizophrenia is a complex, heterogeneous behavioural and cognitive syndrome that seems to originate from disruption of brain development caused by genetic or environmental factors, or both. Dysfunction of dopaminergic neurotransmission contributes to the genesis of psychotic symptoms, but evidence also points to a widespread and variable involvement of other brain areas and circuits. Disturbances of synaptic function might underlie abnormalities of neuronal connectivity

Lancet2016

79. Origin and schizophrenia in young refugees and inter-country adoptees from Latin America and East Africa in Sweden: a comparative study

Origin and schizophrenia in young refugees and inter-country adoptees from Latin America and East Africa in Sweden: a comparative study 27703747 2018 11 13 2056-4724 2 1 2016 Jan BJPsych open BJPsych Open Origin and schizophrenia in young refugees and inter-country adoptees from Latin America and East Africa in Sweden: a comparative study. 6-9 Migrants' socioeconomic adversity has been linked to schizophrenia. To investigate whether the more favourable socioeconomic situation of adoptees (...) prevents them from the high risk of schizophrenia found in other migrants. Register study in a cohort of refugees and inter-country adoptees aged 16-40 years, born in East Africa ( n =8389), Latin America ( n =11 572) and 1.2 million native Swedes. Cox-regression models estimated hazard ratios (HRs) of schizophrenia in data from psychiatric care. Despite diverse income levels, HRs for schizophrenia were similar for refugees and adoptees, with East Africans having the highest HRs: 5.83 (3.30-10.27

BJPsych open2016 Full Text: Link to full Text with Trip Pro

80. Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia

Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia Article Text Psychological interventions Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia Shaun M Eack Correspondence to University of Pittsburgh

Evidence-Based Mental Health2016